Vol. I · No. 037 · The Profile
LEVEL.
The chemistry lab that decided cannabis deserved a tablet.
The MarkThe black tablet wordmark - functional, clinical, unsubtle.
Somewhere in a Santa Rosa lab, a small white tablet sits on a steel tray. It looks like an aspirin. It is not an aspirin. It contains a precisely measured ratio of THC, CBG and a third cannabinoid the average shopper has never heard of - and once swallowed, it will do exactly what the label promised, for the next four hours, with the kind of repeatability normally reserved for pharmacology.
This is LEVEL. Not a dispensary. Not a gummy company. A chemistry shop that decided cannabis should arrive in your bloodstream the way medicine does - on time, on spec, and without dragging in a kilo of sugar to make the dosing palatable.
The pitch is heretical inside an industry built on candy, chocolate and vape pens: cannabis can be a tablet. Tablets can be effects-specific. Effects can be engineered. Engineering can be patented. And once you have all that, the gummy bear starts to look like a costume.
Figures illustrative of LEVEL's effect-based marketing categories.
You don't expect the founder of a cannabis brand to have spent his early twenties translating Mandarin for the United States Navy. You especially don't expect him to have followed that with a PhD in organic chemistry and a postdoc in small-molecule synthesis at Stanford. But Chris Emerson collected both before deciding the most interesting molecules he could work on were not in a pharma pipeline - they were sitting in a plant most chemists weren't allowed to touch.
He started LEVEL in 2015 with a thesis that has aged well: cannabis dosing is sloppy because the form factor is sloppy. Brownies have unknowable bioavailability. Vape pens vary by hardware. Gummies melt, taste like candy, and bury the active in a confection. A swallowable tablet, by contrast, is a controlled environment - a press, a binder, a coating, a known dose, a known curve.
The Protab was the first artifact of that thesis. Then came the Hashtab, which manages the trick of getting an authentic hash high into something the size of a baby aspirin. The Rosintab translated live rosin - the flavor-of-the-month concentrate - into a tablet. And the Tablingual, the strangest item in the lineup, dissolves under your tongue in minutes and skips the liver entirely.
Four products. One thesis. Two patents in the cabinet.
"An authentic, clean, functional high that maximizes the targeted effects and therapeutic benefits."- LEVEL, on the record
LEVEL's product line reads less like a menu and more like a chemistry kit.
The flagship. A swallowable tablet, 10-100mg, calorie-free, vegan, 3-6 hours of effect. The product that built the brand.
An authentic hash high - sativa or indica - delivered in a tablet. The chemistry trick most edibles don't bother attempting.
Live rosin, solventless, translated into oral dosing. For the concentrate connoisseur who doesn't want to dab on a Tuesday.
Dissolves under the tongue. Onset closer to a tincture than an edible. Bypasses the liver pathway entirely.
What people actually do with LEVEL is not what they do with most cannabis products. They don't get high accidentally. They don't double-dose because the gummy looked small. They open a tube, read a label that lists cannabinoids by milligram, and pick the one whose effect they want.
The sleeper goes for a CBN-heavy Tablingual at 9:45pm and is in bed by 10:15. The focused worker picks the Protab+ BOOST with THCv and CBG and goes back to a spreadsheet. The chronic-pain user buys a 100mg Protab and gets a six-hour window of relief that doesn't require lighting anything. The connoisseur buys a Hashtab because hash deserves a tablet too.
It is, in other words, a brand for the cannabis consumer who would like to read the label and have it mean something.
The small white tablet on the steel tray in Santa Rosa has not moved. But the room around it has. A decade ago it would have looked absurd - a pharmaceutical artifact in an industry that sold its product in glass jars and brownie tins. Today it is the leading cannabis tablet in California, sold across hundreds of dispensaries, with two patents behind it and a half-tablet sibling for people who want to take less than ten milligrams of weed without doing math in a parking lot.
LEVEL didn't invent cannabis. It barely even invented the tablet. What it invented is the idea that a cannabis consumer might want the same predictability they get from every other thing they put in their body - and that delivering that predictability is a chemistry problem, not a marketing one.
The tray is steel. The dose is exact. The label tells the truth. That, in this industry, still counts as a quiet act of rebellion.